OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
| Restructuring Cost and Reserve [Line Items] |
|
| SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS |
The
following table presents information related to stock options as of December 31, 2025:
SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS
| Options Outstanding | | |
Options Exercisable | |
| | | |
| | |
Weighted Average | | |
Exercisable | |
| Exercise | | |
Number of | | |
Remaining Life | | |
Number of | |
| Price | | |
Options | | |
In Years | | |
Options | |
| $ |
Under 9.99 | | |
| 2,715,000 | | |
| 8.7 | | |
| 2,715,000 | |
| |
10.00-19.99 | | |
| 15,000 | | |
| 7.4 | | |
| 15,000 | |
| |
20.00-49.99 | | |
| 3,000 | | |
| 3.2 | | |
| 3,000 | |
| |
50.00-69.99 | | |
| 3,000 | | |
| 4.0 | | |
| 3,000 | |
| |
| | |
| 2,736,000 | | |
| 8.7 | | |
| 2,736,000 | |
|
| SCHEDULE OF STOCK OPTION ACTIVITY |
A
summary of the stock option activity and related information for the Plan for the years ended December 31, 2025 and 2024 is as follows:
SCHEDULE OF STOCK OPTION ACTIVITY
| | |
Shares | | |
Weighted
Average
Exercise Price | | |
Weighted
Average Remaining
Contractual Term | | |
Aggregate
Intrinsic Value | |
| Outstanding as of January 1, 2024 | |
| 603,229 | | |
$ | 25.67 | | |
| 6.7 | | |
$ | - | |
| Issued | |
| 2,400,000 | | |
$ | 0.45 | | |
| | | |
$ | - | |
| Forfeited/expired | |
| (488,029 | ) | |
$ | 28.97 | | |
| | | |
| - | |
| Outstanding as of December 31, 2024 | |
| 2,515,200 | | |
$ | 0.96 | | |
| 9.6 | | |
$ | 2,501,040 | |
| Issued | |
| 250,000 | | |
$ | 0.84 | | |
| 9.3 | | |
$ | - | |
| Forfeited/expired | |
| (29,200 | ) | |
$ | 17.34 | | |
| - | | |
| - | |
| Outstanding at December 31, 2025 | |
| 2,736,000 | | |
$ | 0.78 | | |
| 8.7 | | |
$ | 6,744,540 | |
| Exercisable at December 31, 2025 | |
| 2,736,000 | | |
$ | 0.78 | | |
| 8.7 | | |
$ | 6,744,540 | |
|
| SCHEDULE OF OPTIONS GRANTED ASSUMPTIONS USING BLACK-SCHOLES OPTION |
During
the year ended December 31, 2025, the Company granted options to purchase shares of its common stock, which were valued using the Black-Scholes
option pricing model. The following assumptions were used to calculate the fair value of the options granted during the years ended December
31, 2025, and 2024:
SCHEDULE OF OPTIONS GRANTED ASSUMPTIONS USING BLACK-SCHOLES OPTION
| Assumption | |
2025 | | |
2024 | |
| Weighted average grant date fair value | |
$ | 0.80 | | |
$ | 0.40 | |
| Expected volatility | |
| 122.43 | % | |
| 135.60 | % |
| Risk-free interest rate | |
| 4.32 | % | |
| 3.50 | % |
| Expected dividend yield | |
| 0.00 | % | |
| 0.00 | % |
| Expected Term (in years) | |
| 10.0 | | |
| 5.5 | |
|
| SCHEDULE OF INFORMATION RELATED TO WARRANTS |
The
following table summarizes information with respect to outstanding warrants to purchase common stock of Streamex Corp. as of December
31, 2025:
SCHEDULE OF INFORMATION RELATED TO WARRANTS
| Exercise Price | | |
Number of Warrants | | |
Expiration Date |
| $ | 0.3000 | | |
| 11,982 | | |
Nov-29 |
| | 0.9547 | | |
| 665,900 | | |
Sep-28 |
| | 3.3640 | | |
| 117,828 | | |
Jul-29 |
| | 4.0660 | | |
| 25,000 | | |
Nov-32 |
| | 4.4550 | | |
| 107,483 | | |
Jun-28 |
| | 4.6626 | | |
| 5,580 | | |
Apr-29 |
| | 4.9252 | | |
| 49,550 | | |
Mar-29 |
| | 4.9290 | | |
| 71,593 | | |
Mar-29 |
| | 5.1358 | | |
| 99,243 | | |
Jul-28 |
| | 7.1810 | | |
| 83,270 | | |
Jul-28 |
| | 7.5020 | | |
| 9,846 | | |
Jul-28 |
| | 7.9630 | | |
| 21,369 | | |
Aug-28 |
| | 9.0000 | | |
| 21,709 | | |
Jun-27 |
| | 9.5960 | | |
| 84,390 | | |
Jan-29 |
| | 10.0992 | | |
| 19,118 | | |
Aug-28 |
| | 10.2600 | | |
| 51,705 | | |
Sep-28 |
| | 10.4678 | | |
| 84,296 | | |
Sep-28 |
| | 11.3000 | | |
| 40,417 | | |
Oct-28 |
| | 13.2800 | | |
| 96,198 | | |
Nov-28 |
| | 48.0000 | | |
| 12,500 | | |
Jul-26 |
| | 61.6000 | | |
| 56,892 | | |
Nov-27 |
| | | | |
| 1,735,869 | | |
|
|
| SCHEDULE OF WARRANT ACTIVITY |
A
summary of the warrant activity for the years ended December 31, 2025 and 2024 is as follows:
SCHEDULE
OF WARRANT ACTIVITY
| | |
Shares | | |
Weighted
Average
Exercise
Price | | |
Weighted
Average
Remaining
Contractual
Term | | |
Aggregate
Intrinsic
Value | |
| Outstanding as of January 1, 2024 | |
| 2,748,371 | | |
$ | 7.40 | | |
| 3.7 | | |
$ | 1,717 | |
| Issued | |
| 2,202,697 | | |
$ | 2.00 | | |
| 5.0 | | |
| - | |
| Exercised | |
| (51,352 | ) | |
$ | 0.30 | | |
| - | | |
| - | |
| Outstanding as of December 31, 2024 | |
| 4,899,716 | | |
$ | 4.88 | | |
| 3.5 | | |
$ | 405 | |
| Issued | |
| 758,514 | | |
$ | 0.95 | | |
| 3.0 | | |
| - | |
| Forfeited/expired | |
| (886,206 | ) | |
$ | 41.32 | | |
| - | | |
| - | |
| Repurchased for cash (Fundamental Transaction election) | |
| (678,778 | ) | |
$ | 2.07 | | |
| - | | |
| - | |
| Exercised | |
| (2,357,377 | ) | |
$ | 2.41 | | |
| - | | |
| - | |
| Outstanding at December 31, 2025 | |
| 1,735,869 | | |
$ | 6.94 | | |
| 2.8 | | |
$ | 1,415 | |
| Vested and expected to vest at December 31, 2025 | |
| 1,735,869 | | |
$ | 6.94 | | |
| 2.8 | | |
$ | 1,415 | |
| Exercisable at December 31, 2025 | |
| 1,735,869 | | |
$ | 6.94 | | |
| 2.8 | | |
$ | 1,415 | |
|
| SCHEDULE OF RESTRICTED STOCK ACTIVITY |
The
following table summarizes the restricted stock activity for the years ended December 31, 2025 and 2024:
SCHEDULE
OF RESTRICTED STOCK ACTIVITY
| Restricted shares issued as of January 1, 2024 | |
| 163,250 | |
| Granted | |
| 4,605,000 | |
| Vested and issued | |
| (3,075,659 | ) |
| Forfeited | |
| (306,752 | ) |
| Restricted shares issued as of December 31, 2024 | |
| 1,385,839 | |
| Granted | |
| 19,373,980 | |
| Vested and issued | |
| (18,658,156 | ) |
| Forfeited | |
| (64,163 | ) |
| Restricted shares issued as of December 31, 2025 | |
| 2,037,500 | |
| Comprised of: | |
| | |
| Vested restricted shares as of December 31, 2025 | |
| - | |
| Unvested restricted shares as of December 31, 2025 | |
| 2,037,500 | |
|
| Viral Clear Pharmaceuticals Inc [Member] |
|
| Restructuring Cost and Reserve [Line Items] |
|
| SCHEDULE OF RESTRICTED STOCK ACTIVITY |
The
following table summarizes the restricted stock activity for the years ended December 31, 2025 and 2024:
SCHEDULE OF RESTRICTED STOCK ACTIVITY
| Restricted shares issued as of January 1, 2024 | |
| 1,078,679 | |
| Forfeited | |
| (400,000 | ) |
| Restricted shares outstanding at December 31, 2024 | |
| 678,679 | |
| Forfeited | |
| - | |
| Total restricted shares outstanding at December 31, 2025 | |
| 678,679 | |
| | |
| | |
| Comprised of: | |
| | |
| Vested restricted shares as of December 31, 2025 | |
| 678,679 | |
| Unvested restricted shares as of December 31, 2025 | |
| - | |
| Total | |
| 678,679 | |
|
| Viral Clear Pharmaceuticals Inc [Member] |
|
| Restructuring Cost and Reserve [Line Items] |
|
| SCHEDULE OF INFORMATION RELATED TO WARRANTS |
The
following table presents information related to warrants (ViralClear) at December 31, 2025:
SCHEDULE
OF INFORMATION RELATED TO WARRANTS
| Exercise | | |
Number | | |
Expiration | |
| Price | | |
Outstanding | | |
Date | |
| $ | 5.00 | | |
| 473,772 | | |
| November 2027 | |
|
| SCHEDULE OF WARRANT ACTIVITY |
A
summary of the warrant activity for year ended December 31, 2025 is as follows:
SCHEDULE
OF WARRANT ACTIVITY
| | |
| | |
| | |
Weighted-Average | |
| | |
| | |
| | |
Remaining | |
| | |
| | |
Weighted-Average | | |
Contractual | |
| | |
Shares | | |
Exercise Price | | |
Term | |
| Outstanding at January 1, 2024 | |
| 480,347 | | |
$ | 5.07 | | |
| 3.9 | |
| Forfeited/expired | |
| - | | |
| | | |
| | |
| Outstanding at December 31, 2024 | |
| 480,347 | | |
$ | 5.07 | | |
| 2.9 | |
| Forfeited/expired | |
| (6,575 | ) | |
$ | 10.00 | | |
| | |
| Outstanding at December 31, 2025 | |
| 473,772 | | |
$ | 5.00 | | |
| 1.9 | |
| Exercisable at December 31, 2025 | |
| 473,772 | | |
$ | 5.00 | | |
| 1.9 | |
|
| BioSig AI Sciences, Inc. [Member] |
|
| Restructuring Cost and Reserve [Line Items] |
|
| SCHEDULE OF INFORMATION RELATED TO WARRANTS |
The
following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig AI at December 31, 2025:
SCHEDULE
OF INFORMATION RELATED TO WARRANTS
| Exercise | | |
Number | | |
Expiration | |
| Price | | |
Outstanding | | |
Date | |
| $ | 1.00 | | |
| 130,500 | | |
| June-July 2028 | |
|